Navigation Links
How the brain learns to become addicted

Researchers have identified a key signaling molecule in the brain that appears to trigger the brain to "learn" a craving for cocaine. Their finding could offer an important target for drugs to treat addiction by short-circuiting that adaptive process.

In an article in the February 16, 2006, issue of Neuron, Antonello Bonci and colleagues established that a short protein, or peptide, called orexin A acts on a brain region central to the adaptation to addictive drugs. Specifically, they found in their studies with rats that orexin A induces an adaptation that is necessary for the development of behaviors associated with drug-craving in human addicts. The latest findings follow an earlier discovery by the same group that another molecule, corticotropin releasing factor (CRF), acts similarly.

Such adaptations are believed to create a need that is far more compelling than the simple memory of drug-induced pleasure and represent a "rewiring" of the brain into an addictive state.

In a preview article on the paper in the same issue of Neuron, NIH neuroscientist Roy Wise commented that "Inasmuch as arousal or stress can trigger drug-seeking in drug-free animals, the neuroadaptations discovered by the Bonci group are important not only for how rewarding the drug is after an animal starts taking it, but, perhaps more importantly, for how likely the animal is to initiate drug-seeking during periods of abstinence.

"Because it is during periods of abstinence, not periods of intoxication, that addicts seek treatment, the peptide signaling pathways for orexin and CRF may prove to be fruitful targets in the search for addiction medications."

Bonci and his colleagues based their experiments on past studies by other researchers showing that orexins are important regulatory peptides released by a brain center called the lateral hypothalamus. It was also known that orexins tend to activate circuitry in a region called the ventral tegmental area (VT A), known to be a critical site of neural adaptation, or plasticity, induced by addictive drugs. However, it wasn't known whether orexin actually induced such plasticity.

In experiments with rat brain slices, the researchers demonstrated that orexin A does increase activity of neurons in the VTA associated with such plasticity.

And in experiments with whole animals, the researchers found that orexin A was required for "behavioral sensitization" to cocaine. This sensitization shows itself as a long-lasting increase in activity by the animals when they receive the drug and is an indicator that the animals are experiencing an increased craving for the drug.

Importantly, when the researchers "microinjected" directly into the VTA region of animals a drug that blocks orexin receptors, they found they could block the development of behavioral sensitization.

"The findings presented here establish a potential mechanism for the role of orexin signaling in plasticity related to addiction," concluded the researchers. The researchers wrote that this orexin-induced plasticity in the VTA "is likely an important substrate of behaviors relevant to addiction, as we show that activation of [orexin] receptors in the VTA is necessary for the development of cocaine-mediated behavioral sensitization. Thus, orexin receptors may provide novel pharmacotherapeutic targets for motivational disorders such as addiction.


'"/>

Source:Cell Press


Related biology news :

1. Controversial drug shown to act on brain protein to cut alcohol use
2. Mouse brain cells rapidly recover after Alzheimers plaques are cleared
3. Mouse brain tumors mimic those in human genetic disorder
4. New imaging method gives early indication if brain cancer therapy is effective, U-M study shows
5. First atlas of key brain genes could speed research on cancer, neurological diseases
6. NYU study reveals how brains immune system fights viral encephalitis
7. Stem cells from brain transformed to produce insulin at Stanford
8. Birds brains reveal source of songs
9. Loves all in the brain: fMRI study shows strong, lateralized reward, not sex, drive
10. Revolutionary nanotechnology illuminates brain cells at work
11. A puzzle piece found in unraveling the wiring of the brain
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/20/2016)... -- VoiceIt is excited to announce its new marketing ... working together, VoiceIt and VoicePass will offer an ... slightly different approaches to voice biometrics, collaboration between ... Both companies ... "This marketing and technology partnership allows VoiceIt ...
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com , ... published the overview results from the Q1 wave of ... recent wave was consumers, receptivity to a program where ... with a health insurance company. "We were ... share," says Michael LaColla , CEO of Troubadour ...
(Date:5/3/2016)... 3, 2016  Neurotechnology, a provider of high-precision ... Automated Biometric Identification System (ABIS) , a complete ... MegaMatcher ABIS can process multiple complex biometric transactions ... of fingerprint, face or iris biometrics. It leverages ... and MegaMatcher Accelerator , which have been ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... ... 2016 , ... Supplyframe, the Industry Network for electronics hardware ... . Located in Pasadena, Calif., the Design Lab’s mission is to bring together ... built and brought to market. , The Design Lab is Supplyframe’s physical representation ...
(Date:6/23/2016)... ... 2016 , ... In a new case report published today in STEM CELLS ... developed lymphedema after being treated for breast cancer benefitted from an injection of stem ... with this debilitating, frequent side effect of cancer treatment. , Lymphedema refers ...
(Date:6/23/2016)... NEWPORT BEACH, Calif. , June 23, 2016 /PRNewswire/ ... offering new biological discoveries to the medical community, has ... and co-founder Matthew Nunez . "We ... provide us with the capital we need to meet ... funding will essentially provide us the runway to complete ...
(Date:6/23/2016)... YORK , June 23, 2016 ... trading session at 4,833.32, down 0.22%; the Dow Jones Industrial ... S&P 500 closed at 2,085.45, down 0.17%. Stock-Callers.com has initiated ... INFI ), Nektar Therapeutics (NASDAQ: NKTR ), ... Therapeutics Inc. (NASDAQ: BIND ). Learn more about ...
Breaking Biology Technology: